ReviewGlobalization and health2022
COVID-19 data are messy: analytic methods for rigorous impact analyses with imperfect data.
Review in Globalization and health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Sensitivity of machine learning regression models to data structure and quality in crop yield prediction.PloS one · 2026Article
- The spatiotemporal dynamics of COVID-19 in Europe: time-series clustering maps 5 distinct trajectories to spatial patterns.Population health metrics · 2025Article
- Fine-grained forecasting of COVID-19 trends at the county level in the United States.NPJ digital medicine · 2025Article
- Why is it important to implement meta-research in universities and institutes with medical research activities?Frontiers in research metrics and analytics · 2025Article
- Impact of non-pharmaceutical interventions on COVID-19 incidence and deaths: cross-national natural experiment in 32 European countries.BMC public health · 2024Article
- Pandemic preparedness improves national-level SARS-CoV-2 infection and mortality data completeness: a cross-country ecologic analysis.Population health metrics · 2024Article
- How has research on the effectiveness and safety of COVID-19 vaccination been evaluated: a scope review with emphasis on CoronaVac.Frontiers in public health · 2024Review
- The barriers, facilitators and association of vaccine certificates on COVID-19 vaccine uptake: a scoping review.Globalization and health · 2023Article
- Does it matter that standard preparedness indices did not predict COVID-19 outcomes?Globalization and health · 2023Article
- Data quality model for assessing public COVID-19 big datasets.The Journal of supercomputing · 2023Article
- Quantifying the impact of COVID-19 on essential health services: a comparison of interrupted time series analysis using Prophet and Poisson regression models.Journal of the American Medical Informatics Association : JAMIA · 2023Article
- Variations in national surveillance reporting for Mpox virus: A comparative analysis in 32 countries.Frontiers in public health · 2023Article
- Influenza vaccination may have only minimum or no effect on COVID-19 in the aged population.BMJ global health · 2022Article
- Cross-border mobility responses to COVID-19 in Europe: new evidence from facebook data.Globalization and health · 2022Article
- Urban pandemic response: Survey results describing the experiences from twenty-five cities during the COVID-19 pandemic.PLOS global public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic has led to an avalanche of scientific studies, drawing on many different types of data. However, studies addressing the effectiveness of government actions against COVID-19, especially non-pharmaceutical interventions, often exhibit data problems that threaten the validity of their results. This review is thus intended to help epidemiologists and other researchers identify a set of data issues that, in our view, must be addressed in order for their work to be credible. We further intend to help journal editors and peer reviewers when evaluating studies, to apprise policy-makers, journalists, and other research consumers about the strengths and weaknesses of published studies, and to inform the wider debate about the scientific quality of COVID-19 research.
resultsTo this end, we describe common challenges in the collection, reporting, and use of epidemiologic, policy, and other data, including completeness and representativeness of outcomes data; their comparability over time and among jurisdictions; the adequacy of policy variables and data on intermediate outcomes such as mobility and mask use; and a mismatch between level of intervention and outcome variables. We urge researchers to think critically about potential problems with the COVID-19 data sources over the specific time periods and particular locations they have chosen to analyze, and to choose not only appropriate study designs but also to conduct appropriate checks and sensitivity analyses to investigate the impact(s) of potential threats on study findings.
conclusionsIn an effort to encourage high quality research, we provide recommendations on how to address the issues we identify. Our first recommendation is for researchers to choose an appropriate design (and the data it requires). This review describes considerations and issues in order to identify the strongest analytical designs and demonstrates how interrupted time-series and comparative longitudinal studies can be particularly useful. Furthermore, we recommend that researchers conduct checks or sensitivity analyses of the results to data source and design choices, which we illustrate. Regardless of the approaches taken, researchers should be explicit about the kind of data problems or other biases that the design choice and sensitivity analyses are addressing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.